Abstract

ObjectivesTo assess the effects of Rituximab (RTX) on skin and lung fibrosis in patients with systemic sclerosis (SSc) belonging to the European Scleroderma Trial and Research (EUSTAR) cohort and using...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.
Minoru Hasegawa ... Koji Oba
The Lancet. Rheumatology | VOL. 3
Minoru Hasegawa, et. al.Minoru Hasegawa ... Koji Oba
01 Jul 2021
A BENEFICIAL EFFECT OF LONG-TERM TREATMENT OF RITUXIMAB IN INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS
Liudmila Garzanova ... Lidia Ananyeva
Chest | VOL. 162
Liudmila Garzanova, et. al.Liudmila Garzanova ... Lidia Ananyeva
01 Oct 2022
SAT0274 THE EFFECT OF RITUXIMAB ON LUNG FUNCTION AND SKIN SCORE IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. LONG-TERM OBSERVATION
Oxana Desinova ... Alexander Volkov
-
Oxana Desinova, et. al.Oxana Desinova ... Alexander Volkov
01 Jun 2019
FRI0264 Treatment with rituximab in patients with systemic sclerosis
O Ovsyannikova ... M Starovoytova
Annals of the Rheumatic Diseases | VOL. 71
O Ovsyannikova, et. al.O Ovsyannikova ... M Starovoytova
01 Jun 2013
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers